AI Assistant
Blog
Pricing
Log In
Sign Up
A real-world study of anlotinib as third-line or above therapy in patients with her-2 negative metastatic breast cancer
Details
Cite
Export
Add to List
The content you want is available to Zendy users.
Already have an account? Click
here.
to sign in.
